Hopp til hovedinnhold

Herpes zoster

Sist oppdatert: Sist revidert:
Sist revidert av:

Hudinfeksjon forårsaket av varicella-zoster-virus
Insidens er ca 2 pr 1000 innbyggere pr år
Starter med avgrensede, brennede smerter. Etter noen dager får pasienten vesikulært utslett, ev. feber
Ensidig vesikulært utslett i ett dermatom
Tilleggsprøver vanligvis ikke nødvendig
I den akutte fasen anbefales smertebehandling. Spesifikk antiviral terapi kan være aktuelt hos eldre
  1. Kofoed K, Rønholt F, Gerstoft J, Sand C. Herpes zoster: klinik, diagnostik og behandling. Ugeskr Læger 2011; 173: 114. Ugeskrift for Læger  
  2. Saguil A, Kane S, Mercado M, Lauters R. Herpes zoster and postherpetic neuralgia: Prevention and management. Am Fam Physician 2017 Nov 15;96(10):656-663. PubMed  
  3. Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician 2011; 83: 1432-7. American Family Physician  
  4. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341. PubMed  
  5. Johnson BH, Palmer L, Gatwood J, et al. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis. 2015;15:502. PubMed  
  6. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20: 748-53. PubMed  
  7. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med 2002; 347: 340-6. PubMed  
  8. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84. New England Journal of Medicine  
  9. Wang Y-P, Liu C-J, Hu Y-W, et al. Risk of cancer among patients with herpes zoster infection: a population-based study. CMAJ 2012. doi:10.1503/CMAJ.120518 DOI  
  10. Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005; 40: 169. PubMed  
  11. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for herpes zoster: population based case-control study. BMJ 2014; 348: g2911. BMJ (DOI)  
  12. Wang YP, Liu CJ, Hu YW, et al. Risk of cancer among patients with herpes zoster infection: a population-based study. CMAJ 2012 Oct 16; 184(15): E804-9. PMID: 22988158. PubMed  
  13. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1: S1.
  14. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of post-herpetic neuralgia after a first episode of herpes zoster: a prospective study with long term follow up. BMJ 2000; 321: 794-6. PubMed  
  15. Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191: 2002. PubMed  
  16. Albrecht MA. Clinical manifestations of varicella-zoster virus infection: Herpes zoster. UpToDate, last updated Aug 02, 2016. UpToDate  
  17. Albrecht MA. Treatment of herpes zoster in the immunocompetent host. UpToDate, last updated Jul 21, 2016. www.uptodate.com  
  18. Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005; 65: 444-7. Neurology  
  19. Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD005582. DOI: 10.1002/14651858.CD005582.pub4. DOI  
  20. Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866. PMID: 24500927 PubMed  
  21. Wood MJ, Shukla S, FIddian AP, Crooks RJ. Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis 1998; 178 (Suppl 1): S81-S84.
  22. Pasternak B, Hviid A. Use of acyclovir, valacyklovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304: 859-66. Journal of the American Medical Association  
  23. Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Br J Ophthalmol 2000; 107: 1507-11. PubMed  
  24. Alper BS, Lewis PR. Does treatment of Acute Herpes Zoster Prevent or Shorten Postherpetic Neuralgia? A Systematic Review of the Literature. J Fam Pract 2000, 49;3:255-64.
  25. Gagliardi AMZ, Andriolo BNG, Torloni MR, Soares BGO, de Oliveira Gomes J, Andriolo RB, Canteiro Cruz E. Vaccines for preventing herpes zoster in older adults. Cochrane Database of Systematic Reviews 2019, Issue 11. Art. No.: CD008858. DOI: 10.1002/14651858.CD008858.pub4. Accessed 10 May 2022 The Cochrane Library  
  26. Forbes H, Douglas I, Finn A, et al. Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: self controlled case series study using UK electronic healthcare data. BMJ 2020; 368: l6987. pmid:31969318 PubMed  
  27. Weinmann S, Chun C, Schmid DS, et al. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009. J Infect Dis 2013; 208: 1859-68. doi:10.1093/infdis/jit405
  28. Breuer J, Pacoud M, Gauthier A, Brown MM. Herps zoster as a risk factor for stroke and TIA. Neurology 2014. doi:10.1212/WNL.0000000000000038 DOI  
  29. Thyregod HG, Rowbotham MC, Peters M, Possehn J, Berro M, Petersen KL. Natural history of pain following herpes zoster. Pain 2007; 128: 148-156. PubMed  
  30. Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012; 206: 190-6. PubMed  
  31. Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the Shingles Prevention Study: A randomized trial. Ann Intern Med 2010; 152: 545-54. Annals of Internal Medicine  
  32. Kawai K, Preaud E, Baron-Papillon F, et al. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine. 2014 ;32(15):1645-53. doi: 10.1016/j.vaccine.2014.01.058 DOI  
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL

Tidligere fagmedarbeidere

  • Sylvi Torvund, spesialist i allmennmedisin, Nidarvold legesenter, Trondheim
  • Kristin Ryggen, overlege, Hudavdelingen, Regionsykehuset i Trondheim